Trials / Completed
CompletedNCT01850602
A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 213 (actual)
- Sponsor
- Kissei Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of PA21 in hemodialysis patients with hyperphosphatemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PA21 | |
| DRUG | Sevelamer hydrochloride |
Timeline
- Start date
- 2013-04-23
- Primary completion
- 2013-12-01
- Completion
- 2013-12-10
- First posted
- 2013-05-09
- Last updated
- 2018-10-09
- Results posted
- 2018-10-09
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01850602. Inclusion in this directory is not an endorsement.